Background: Recent evidence suggests a better reduction rate of some uremic toxins with expanded hemodialysis (HDx). Methods: Prospective study including 8 hemodialysis patients. We divided the study in 2 phases; within the first one, we assigned 4 patients (group 1) to undergo online hemodiafiltration with a PF 210H dialyzer, and the other 4 patients (group 2) to undergo HDx with the high retention onset Theranova 500 dialyzer during 24 sessions. Later, during the second phase and after a washout period, the same patients were switched to receive HDx (group 1) and HDF (group 2). Results: No differences were found in the Urea and β2-microglobulin reduction ratio. However, in the case of myoglobin, the reduction ratio with HDF was 35 vs. 60% with HDx (p < 0.001). Similarly, in the case of prolactin, the reduction ratio with HDF was 45 and 61% with HDx (p < 0.001). Conclusions: We conclude that HDx is not inferior to online hemodiafiltration in the clearance of small and middle molecules and could be superior in the clearance of larger middle molecules.

Keywords:
Expanded hemodialysis, Middle molecules, Hemodialysis adequacy, Online hemodiafiltration
1.
Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; ­European Uremic Toxin Work Group: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23: 1258–1270.
2.
Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999; 10: 1815–1823.
3.
Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R: Inconsistency of reported uremic toxin concentrations. Artif Organs 2007; 31: 600–611.
4.
Moradi H, Sica DA, Kalantar-Zadeh K: Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease. Am J Nephrol 2013; 38: 136–148.
5.
Ma L, Zhao S: Risk factors for mortality in patients undergoing hemodialysis: a systematic review and meta-analysis. Int J Cardiol 2017; 238: 151–158.
6.
Ronco C, Clark WR: Haemodialysis membranes. Nat Rev Nephrol 2018; 14: 394–410.
7.
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R; Hemodialysis (HEMO) Study Group: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347: 2010–2019.
8.
Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V, Jacobson SH, Czekalski S, Ronco C, Vanholder R; Membrane Permeability Outcome (MPO) Study Group: Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009; 20: 645–654.
9.
Canaud B, NGuyen QV, Polito C, Stec F, Mion C: Hemodiafiltration with on-line production of bicarbonate infusate. A new standard for high-efficiency, low-cost dialysis in elderly and uncompliant patients. Contrib Nephrol 1989; 74: 91–100.
10.
Maduell F, Sanchez-Canel JJ, Blasco JA, Navarro V, Rius A, Torregrosa E, Pin MT, Cruz C, Ferrero JA: [Middle molecules removal. Beyond beta2-microglobulin]. Nefrologia 2006; 26: 469–475.
11.
Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, den Hoedt CH, van der Tweel I, Levesque R, Nube MJ, ter Wee PM, Blankestijn PJ; CONTRAST Investigators: Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23: 1087–1096.
12.
Maduell F, Moreso F, Pons M, Ramos R, ­Mora-Macia J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A; ESHOL Study Group: High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487–497.
13.
Ok E, Asci G, Toz H, Ok ES, Kircelli F, Yilmaz M, Hur E, Demirci MS, Demirci C, Duman S, Basci A, Adam SM, Isik IO, Zengin M, Suleymanlar G, Yilmaz ME, Ozkahya M; Turkish Online Haemodiafiltration Study: Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28: 192–202.
14.
Mazairac AH, Blankestijn PJ, Grooteman MP, Penne EL, van der Weerd NC, den Hoedt CH, Buskens E, van den Dorpel MA, ter Wee PM, Nube MJ, Bots ML, de Wit GA; CONTRAST investigators: The cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. Nephrol Dial Transplant 2013; 28: 1865–1873.
15.
Ronco C, La Manna G: Expanded Hemodialysis: A New Therapy for a New Class of Membranes. Contrib Nephrol 2017; 190: 124–133.
16.
Heyne N: Expanded hemodialysis therapy: prescription and delivery. Contrib Nephrol 2017; 191: 153–157.
17.
Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR, Krieter DH: Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant 2017; 32: 165–172.
18.
Ronco C: The rise of expanded hemodialysis. Blood Purif 2017; 44:I–VIII.
19.
Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T, Keshaviah PR: Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Hemodialysis (HEMO) Study. Kidney Int 1997; 51: 2013–2017.
20.
Daugirdas JT: Removal of phosphorus by hemodialysis. Semin Dial 2015; 28: 620–623.
21.
Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W: A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11: 2344–2350.
22.
Lorenzin A, Neri M, Lupi A, Todesco M, Santimaria M, Alghisi A, Brendolan A, Ronco C: Quantification of internal filtration in hollow fiber hemodialyzers with medium cut-off membrane. Blood Purif 2018; 46: 196–204.
23.
Willy K, Girndt M, Voelkl J, Fiedler R, Martus P, Storr M, Schindler R, Zickler D: Expanded haemodialysis therapy of chronic haemodialysis patients prevents calcification and apoptosis of vascular smooth muscle cells in vitro. Blood Purif 2018; 45: 131–138.
24.
Mitra S, Kharbanda K: Effects of expanded hemodialysis therapy on clinical outcomes. Contrib Nephrol 2017; 191: 188–199.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.